我們已在上線!
進一步了解
Humacyte Inc Warrant
HUMAW
HUMAW
已下市
HUMAW已於2026年8月25日下市。
公司簡介: Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
員工: 184
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
價格圖表採用Lightweight Charts™實作